Leukopenija kao jedini simptom Kovid-19 kod pacijenata obolelih od shizofrenije na terapiji klozapinom

Alen Greš; Dijana Staver; Marina Šagud

Alen Greš Klinika za psihijatriju i psihološku medicinu KBC Zagreb, Zagreb, Hrvatska
Dijana Staver Poliklinika za zaštitu djece i mladih Grada Zagreba, Zagreb, Hrvatska
Marina Šagud Klinika za psihijatriju i psihološku medicinu KBC Zagreb, Zagreb, Hrvatska

Ključne reči: Kovid-19, SARS CoV 2, klozapin, shizofrenija, leukopenija, neutropenija, asimptomatski

Sažetak

Pacijenti koji boluju od Kovida-19 često imaju leukopeniju, najčešće limfopeniju, kao prateću laboratorijsku manifestaciju kliničkog sindroma, ali postoje indicije da na početku obolenja imaju i blagu neutropeniju. Klozapin može imati hematološke neželjene efekte u smislu leukopenije – najčešće neutropenije.

U radu je prikazan pacijent sa shizofrenijom koji je na dugogodišnjoj terapiji klozapinom. U trenutku kada se detektovala leukopenija u krvnoj slici, bio je psihički stabilan i telesno asimptomatski. Imao je smanjen broj leukocita kao jedini simptom infekcije novim koronavirusom SARS CoV 2, kojega smo potvrdili PCR-om. U ovom radu prikazujemo kliničku sliku Kovida-19 u vezi sa mogućom etiologijom preklapanja leukopenije koja se takođe može pojaviti i kao zaseban simptom infekcije koronavirusom SARS CoV 2 i biti hematološki neželjeni efekat lečenja klozapinom.

Reference

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020;395:497–506.

Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395: 507–513.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–1062.

Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708–1720.

Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng, Y, et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. International journal of infectious diseases. 2019; 96:131-135.

Wang D, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323: 1061–1069.

Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. Cambridge: Cambridge University Press; 2013.

Li XH, Zhong XM, Lu L. The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med. 2020; 50: 583–594.

Stahl SM. Stahl's Essential Psychopharmacology: The Prescriber's Guide 6th ed. New York: Cambridge University Press; 2017.

Geldenhuys C, Zunza M, Tiffi N, Koen L, Decloedt EH. Clozapine-Associated Leukopenia and Agranulocytosis in Western Cape, South Africa: A 3-Year Retrospective Cohort Study. Journal of Clinical Psychopharmacology. 2021;41(3):250-254.

Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Annals of hematology. 2020;99(11):2477-2482.

Myles N, Myles H, Xia S. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018;138:101–109.

Munshi, HG, Montgomery, RB. Severe neutropenia: a diagnostic approach. West J Med. 2000; 172:248–252.

Zhang, X, Tan, Y, Ling, Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020;583(7816):437-440.

Lowery SA, Sariol A, Perlman S. (2021). Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. Cell Host Microbe. 2021;29(7):1052-1062.

Elbe D, Black TR, McGrane IR, Procyshyn RM. Clinical Handbook of Psychotropic Drugs for Children and Adolescents, 4th ed. Boston: Hogrefe Publishing Corporation; 2019. p.160.

Rajagopal S . Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J. 2005;81:545–546.

Gee S, Taylor D. The effect of COVID-19 on absolute neutrophil counts in patients taking clozapine. Ther Adv Psychopharmacol [Internet]. 2020 Jul 16 [cited 2022 Mar 16];16:10:2045125320940935. Available from: Doi: 10.1177/2045125320940935

Rajić Z, Dunjić B, Milivojević G, Cvetić T, Simončević M, Mirosavljević S, et al. Uspešan oporavak pacijentkinje sa razvojem granulocitopenije tokom terapije klozapinom. Engrami. 2008;30(1):67-72.

De Leon J, Ruan CJ, Schoretsanitis G, De las Cuevas C. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. 2020;89(4):200-214.